Clinical trial
Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer Disease
NCT00480701 is registered in ClinicalTrials.gov with Institute for Neurodegenerative Disorders as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer Disease
- Lead sponsor
- Institute for Neurodegenerative Disorders
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2007
- Completion date
- October 31, 2011
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.